103
Participants
Start Date
January 9, 2017
Primary Completion Date
June 12, 2018
Study Completion Date
June 12, 2018
Iron isomaltoside/ferric derisomaltose
"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion."
Pharmacosmos Investigational Site, Hialeah
Pharmacosmos Investigational Site, Miami Lakes
Pharmacosmos Investigational Site, Miami
Pharmacosmos Investigational Site, Miami
Pharmacosmos Investigational Site, Miami
Pharmacosmos Investigational Site, Doral
Pharmacosmos Investigational Site, West Palm Beach
Pharmacosmos Investigational Site, Chattanooga
Pharmacosmos Investigational Site, Metairie
Pharmacosmos Investigational Site, New Orleans
Pharmacosmos Investigational Site, Baton Rouge
Pharmacosmos Investigational Site, Shreveport
Pharmacosmos Investigational Site, Houston
Pharmacosmos Investigational Site 1, San Antonio
Pharmacosmos Investigational Site 2, San Antonio
Pharmacosmos Investigational Site, Albuquerque
Pharmacosmos Investigational Site, Northridge
Pharmacosmos Investigational Site, Chula Vista
Pharmacosmos Investigational Site 1, La Mesa
Pharmacosmos Investigational Site 2, La Mesa
Pharmacosmos Investigational Site, Porterville
Pharmacosmos Investigational Site, Plainsboro
Lead Sponsor
Pharmacosmos A/S
INDUSTRY